Diabetes and thyroid cancer risk in the national institutes of Health-AARP diet and health study

Thyroid

Volumn 21, Issue 9, 2011, Pages 957-963

  Aschebrook Kilfoy, Briseis ^a   Sabra, Mona M ^b   Brenner, Alina ^a   Moore, Steven C ^a   Ron, Elaine ^a   Schatzkin, Arthur ^a   Hollenbeck, Albert ^c   Ward, Mary H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c AARP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIET; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NATIONAL HEALTH ORGANIZATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; SELF REPORT; SEX DIFFERENCE; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION;

AGE FACTORS; AGED; AGING; CELL DIFFERENTIATION; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; THYROID NEOPLASMS; TIME FACTORS; UNITED STATES;

EID: 80052491953     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2010.0396     Document Type: Article

References (66)

1. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, Anderson WF 2009 Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev 18:1092-1100.
2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, Zhang Y 2009 International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20:525-531.
3. Lew JI, Solorzano CC 2010 Use of ultrasound in the management of thyroid cancer. Oncologist 15:253-258.
4. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS. 2009 Cancer Epidemiol Biomarkers Prev 18:784-791.
5. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS 2003 State-specific prevalence of selected chronic diseaserelated characteristics-behavioral risk factor surveillance system, 2001 MMWR Surveill Summ 52:1-80.
6. Wu P 2000 Thyroid disease and diabetes. Clin Diabetes 18:365-372.
7. Hsu IR, Kim SP, Kabir M, Bergman RN 2007 Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 86:s867-s871.
8. Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, Manjer J, Hallmans G, Selmer R, Almquist M, Häggström C, Engeland A, Tretli S, Concin H, Strasak A, Stattin P, Ulmer H 2010 Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 22:291-299.
9. Gursoy A 2010 Rising thyroid cancer incidence in the world might be related to insulin resistance. Med Hypotheses 74:35-36.
10. Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, Ringel MD 2010 The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab 95:4244-4250.
11. Wolin KY, Carson K, Colditz GA 2010 Obesity Cancer Oncologist 15:556-565.
12. Potenaza M, Via MA, Yanagisawa RT 2009 Excess thyroid hormone and carbohydrate metabolism. Endocr Pract 15:254-262.
13. Udiong CE, Udoh AE, Etukudoh ME 2007 Evaluation of thyroid function in diabetes mellitus in Calabar, Nigeria. IJCB 22:74-78. (Pubitemid 350224132)
14. Hiasa Y, Kitahori Y, Kitamura M, Nishioka H, Yane K, Fukumoto M, Ohshima M, Nakaoka S, Nishii S 1991 Relationships between serum thyroid stimulating hormone levels and development of thyroid tumors in rats treated with N-bis-(2-hydroxypropyl)nitrosamine. Carcinogenesis 12:873-877.
15. Boelaert K 2009 The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer 16:1065-1072.
16. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H 2008A higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93:809-814. (Pubitemid 351398557)
17. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P 2009 Lower levels of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer 16:1251-1260.
18. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW 2007 Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92:2610-2615. (Pubitemid 47037365)
19. Jonklaas J, Nsouli-Maktabi H, Soldin SJ 2008 Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid 18:943-952.
20. Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, Flaris N, Leontsini M, Kourtis A, Avramidis A 2008 Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol 134:953-960.
21. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, Belfiore A 2001 The IGF system in thyroid cancer: new concepts. Mol Pathol 54:121-124. (Pubitemid 32539600)
22. Smith U, Gale EA 2009 Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708.
23. Cléro E, Leux C, Brindel P, Truong T, Anger A, Teinturier C, Diallo I, Doyon F, Guénel P, de Vathaire F 2010 Pooled analysis of two case-control studies in New Caledonia and French Polynesia of body mass index and differentiated thyroid cancer: the importance of body surface area. Thyroid 20:1285-1293.
24. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, Berrington de González A 2010 Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol 171:242-252.
25. Leitzmann MF, Brenner A, Moore SC, Koebnick C, Park Y, Hollenbeck A, Schatzkin A, Ron E 2010 Prospective study of body mass index, physical activity and thyroid cancer. Int J Cancer 126:2947-2956.
26. Bener A, Alsaied A, Al-Ali M, Al-Kubaisi A, Basha B, Abraham A, Guiter G, Mian M 2009 High prevalence of vitamin D deficiency in type 1 diabetes mellitus and healthy children. Acta Diabetol 46:183-189.
27. Toner CD, Davis CD, Milner JA 2010 The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc 110:1492-1500 (review).
28. LaVecchia C, Negri E, Franceschi S, Avanzo BD, Boyle P 1994A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70:950-953. (Pubitemid 24331093)
29. Mack WJ, Preston-Martin S, Bernstein L, Qian D 2002 Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol 12:395-401. (Pubitemid 34823638)
30. Zhan Y, Feng L, Tang S, Li WG, Xu M, Liu TF, ZhouYF, Ma YL, Zhang Y, Pu XM 2009 Glucose metabolism disorders in cancer patients in a Chinese population. Med Oncol 27:177-184.
31. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S 2006 Diabetes mellitus and risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871-1877. (Pubitemid 44455170)
32. Kuriki K, Hirose K, Tajima K 2007 Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J of Cancer Prev 16:83-89. (Pubitemid 46105011)
33. Rousseau MC, Parent ME, Pollack MN, Siemiatycki J 2006 Diabetes mellitus and cancer risk in a population-based casecontrol study among men from Montreal, Canada. Int J Cancer 118:2105-2109.
34. Zivaljevic V, Vlajinac H, Jankovic R, Marinkovic J, Diklic A, Paunovic I 2004 Case-control study of anaplastic thyroid cancer. Tumori 94:9-12. (Pubitemid 38541718)
35. Zendehdel K, Nyren O, Ostenson CG,Adami H, Ekbom A, Ye W 2003 Cancer incidence in patientswith type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797-1800. (Pubitemid 38008903)
36. Wideroff L, Gridley, Mellemkjaer, Chow WH, Linet MS, Keehn S, Borch-Johnsen K, Olsen JH 1994 Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360-1365.
37. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, Berrington de Gonzalez A 2010 Nonradiationrisk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol 171:242-252.
38. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman S, Hacker D, Persson I. 1991 Cancer risk in patients with diabetes- mellitus. Cancer Causes Control 2:307-314.
39. Chodick G, Heymann AD, Rosenmann L, Green MS, Flash S, Porath A, Kokia E, Shalev V 2010 Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 21:879-887.
40. Ron E, Schneider A 2006 Thyroid cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer Epidemiology and Prevention, 3rd edition. Oxford University Press, New York, pp 975-994.
41. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR, Hurwitz PE, Coyle L, Schussler N, Michaud DS, Freedman LS, Brown CC, Midthune D, Kipnis V 2001 Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154:1119-1125.
42. World Health Organization 2001 International Classification of Diseases for Oncology. World Health Organization, Geneva, Switzerland.
43. Michaud DS 2005 Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Registry Manage 32:70-75.
44. Hartl DM, Travagli JP 2009 The updated American thyroid association guidelines for management of thyroid nodules and differentiated thyroid cancer: a surgical perspective. Thyroid 1149-1151.
45. Köhrle J 2007 Thyroid hormone transporters in health and disease: advances in thyroid hormone deiodination. Best Pract Res Clin Endocrinol Metab 21:173-191. (Pubitemid 46888200)
46. Köhrle J 1999 Local activation and inactivation of thyroid hormones: the deiodinase family. Mol Cell Endocrinol 151:103-119.
47. Conn MP, Melmed S 1997 Endocrinology: Basic and Clinical Principles. Part V: Diseases and Systems. Iodothyronine Deiodination. Humana Press, Totowa, NJ.
48. St Germain DL, Galton VA 1997 The deiodinase family of selenoproteins. Thyroid 7:655-658.
49. Dora JM, Machado WE, Rheinheimer J, Crispim D, Maia AL 2010 Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur J Endocrinol 163:427-434.
50. Arnaldi LA, Borra RC, Maciel RM, Cerutti JM 2005 Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 15:210-221. (Pubitemid 40418688)
51. Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, Mizuma H, Mori M 2001 Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 142:2961-2967. (Pubitemid 32575533)
52. De Souza Meyer EL, Dora JM, Wagner MS, Maia AL 2005 Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentiation towards papillary carcinoma. Clin Endocrinol 62:672-678. (Pubitemid 40825936)
53. Kim BW, Daniels GH, Harrison BJ, Price A, Harney JW, Larsen PR, Weetman AP 2003 Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Metab 88:594-598. (Pubitemid 36207796)
54. Takano T, Miyauchi A, Ito Y, Amino N 2006 Thyroxine to triiodothyronine hyperconversion thyrotoxicosis in patients with large metastases of follicular thyroid carcinoma. Thyroid 16:615-618. (Pubitemid 44066270)
55. Dentice M, Ambrosio R, Salvatore D 2009 Role of type 3 deiodinase in cancer. Expert Opin Ther Targets 13:1363-1373.
56. Clemmons DR 1989 Structural and functional analysis of insulin-like growth factors Br Med Bull 45:465-480. (Pubitemid 19116532)
57. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396. (Pubitemid 28209997)
58. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre JDemaille A 1993 Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29:492-497. (Pubitemid 23036292)
59. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625. (Pubitemid 29194048)
60. Paramesweran R, Brooks S, Sadler GP 2010 Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg 8:186-193.
61. Marrero DG 2009 The Prevention of type 2 diabetes: an overview. J Diabetes Sci Technol 3:756-760.
62. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI 2010 Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res 70:8587-8597.
63. Freedman DM, Looker AC, Chang SC, Graubard BI 2007 Prospective study of serum vitamin D and cancer mortality in the United States. Natl Cancer Inst 7:1594-1602.
64. Giovannucci E 2007 Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res 22 Suppl 2:V81-V85 (review). (Pubitemid 351304655)
65. Giovannucci E 2008Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 624:31-42 (review).
66. Macejová D, Ondková S, Brtko J 2009 Vitamin D(3) affects expression of thyroid hormone receptor alpha and deiodinase activity in liver of MNU-treated Sprague-Dawley rats. Gen Physiol Biophys 28:363-370.